Lenalidomide Stada

Lenalidomide, the active ingredient in Lenalidomide Stada, is an immunomodulatory imide drug (IMiD) presented as an oral dosage form for oral administration. It is used in the treatment of certain blood cancers, including multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma.

GNH USA supplies Lenalidomide Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides reliable sourcing for hospitals, pharmacies and clinical trial sites across multiple regions.

Lenalidomide is indicated for several hematologic malignancies, targeting abnormal plasma cells and related disease pathways.

Multiple myeloma: improves progression‑free survival and overall response rates in patients with relapsed or refractory disease. Myelodysplastic syndromes with del(5q): reduces transfusion dependence and can lead to cytogenetic remission. Mantle cell lymphoma: used in combination regimens to achieve disease control in relapsed cases.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: decreased neutrophil count increasing infection risk. - Thrombocytopenia: reduced platelet levels leading to bleeding tendency. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require supportive care.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs, potentially life‑threatening. - Secondary primary malignancies: emergence of new cancers during treatment. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing lenalidomide, clinicians should observe several safety measures.

Pregnancy: contraindicated (Category X); teratogenic risk requires effective contraception. Renal impairment: dose adjustment may be needed; monitor renal function. Hematologic monitoring: regular CBC to detect neutropenia or thrombocytopenia. Thromboembolic risk: consider prophylactic anticoagulation in high‑risk patients. Drug interactions: avoid concomitant use with strong CYP inducers without supervision. Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Lenalidomide has notable interactions that may require avoidance or close monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding when combined with thrombocytopenia.

Moderate Interactions (Monitor Closely): - P‑glycoprotein inhibitors (e.g., verapamil): may increase plasma levels. - Live‑attenuated vaccines: risk of infection due to immunomodulation. - Other immunomodulatory agents (e.g., thalidomide): additive myelosuppression.